Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 6/20 | 0.59 |
| ▸ | ATP4B known ✓ | P51164 | 6/20 | 0.59 |
| ▸ | BRS3 | P32247 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.59 |
| ▸ | ATP1A1 | P05023 | 5/20 | 0.59 |
| ▸ | ATP1B1 | P05026 | 5/20 | 0.59 |
| ▸ | ATP1A3 | P13637 | 5/20 | 0.59 |
| ▸ | ATP1B2 | P14415 | 5/20 | 0.59 |
| ▸ | ATP1A2 | P50993 | 5/20 | 0.59 |
| ▸ | ATP1B3 | P54709 | 5/20 | 0.59 |
| ▸ | FXYD2 | P54710 | 5/20 | 0.59 |
| ▸ | ATP1A4 | Q13733 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.59 |
| ▸ | WDR5 | P61964 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.59 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esomeprazole SCHEMBL29691369 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL28256108 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL1192 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL30426884 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL140006 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL19535 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL29772327 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL29360040 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL265327 | 0.98 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL2867502 | 0.98 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102131799-B | Method for splitting omeprazole salts | UNIV ROUEN | 2014-06-18 | — | — | CN | disclosed |
| US-8034948-B2 | Method for resolving omeprazole salts | UNIVERSITE DE ROUEN (FR) | 2011-10-11 | — | — | US | disclosed |
| CN-102131799-A | Method for splitting omeprazole salts | UNIV ROUEN | 2011-07-20 | — | — | CN | disclosed |
| US-20090124811-A1 | Method for resolving omeprazole salts | UNIVERSITE DE ROUEN (FR) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124811-A1 | Method for resolving omeprazole salts | VKORC1, SI, VKORC1L1 | ATP4A 559/4885ATP4B 608/4885BRS3 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.